BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12629954)

  • 21. [Clinical impact of aripiprazole in patients suffering from schizophrenia].
    Levoyer D; Drapier D; Fadier-Salicé G; Millet B
    Encephale; 2007; 33(3 Pt 1):332-8. PubMed ID: 17675931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole for schizophrenia.
    El-Sayeh HG; Morganti C
    Cochrane Database Syst Rev; 2004; (2):CD004578. PubMed ID: 15106256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation.
    Schlagenhauf F; Dinges M; Beck A; Wüstenberg T; Friedel E; Dembler T; Sarkar R; Wrase J; Gallinat J; Juckel G; Heinz A
    Schizophr Res; 2010 May; 118(1-3):189-200. PubMed ID: 20189356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.
    Stahl SM
    J Clin Psychiatry; 2001 Dec; 62(12):923-4. PubMed ID: 11780870
    [No Abstract]   [Full Text] [Related]  

  • 25. What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
    Deng C; Chen J; Hu C; Huang XF
    J Clin Psychopharmacol; 2010 Aug; 30(4):480-1. PubMed ID: 20631576
    [No Abstract]   [Full Text] [Related]  

  • 26. Schizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazole.
    Salzman C; Rosenberg J; Feldman JJ
    J Clin Psychiatry; 2007 Jun; 68(6):970. PubMed ID: 17592928
    [No Abstract]   [Full Text] [Related]  

  • 27. Aripiprazole: profile on efficacy and safety.
    Goodnick PJ; Jerry JM
    Expert Opin Pharmacother; 2002 Dec; 3(12):1773-81. PubMed ID: 12472374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aripiprazole use in children and adolescent psychiatric patients].
    Chevreuil C; Polard E; Lemonnier E; Guillemot P; Bentué-Ferrer D;
    Therapie; 2011; 66(2):123-30. PubMed ID: 21635859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole versus typicals for schizophrenia.
    Bhattacharjee J; El-Sayeh HG
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006617. PubMed ID: 18254107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)].
    Dorozhenok IY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(12):63-67. PubMed ID: 36537633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
    Cassano GB; Fagiolini A; Lattanzi L; Monteleone P; Niolu C; Sacchetti E; Siracusano A; Vita A
    Clin Drug Investig; 2007; 27(1):1-13. PubMed ID: 17177576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching of antipsychotics to aripiprazole in the treatment of schizophrenia.
    Lin HC; Chong MY; Lee Y; Yeh WC; Lin PY
    Chang Gung Med J; 2009; 32(4):409-16. PubMed ID: 19664347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
    Mace S; Taylor D
    CNS Drugs; 2009 Sep; 23(9):773-80. PubMed ID: 19689167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.
    Fagiolini A; Brugnoli R; Di Sciascio G; De Filippis S; Maina G
    Expert Opin Pharmacother; 2015 Apr; 16(5):727-37. PubMed ID: 25672664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-generation antipsychotic medications in the treatment of mood disorders: focus on aripiprazole.
    Buckley PF
    Drugs Today (Barc); 2005 Jan; 41(1):5-11. PubMed ID: 15753965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second generation antipsychotics--aripiprazole revisited.
    Med Lett Drugs Ther; 2005 Oct; 47(1219):81-2. PubMed ID: 16247339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aripiprazole, a novel atypical antipsychotic drug.
    Argo TR; Carnahan RM; Perry PJ
    Pharmacotherapy; 2004 Feb; 24(2):212-28. PubMed ID: 14998222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole versus placebo for schizophrenia.
    Belgamwar RB; El-Sayeh HG
    Cochrane Database Syst Rev; 2011 Aug; (8):CD006622. PubMed ID: 21833956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.